Cargando…

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) provided significant antitumor activity in various tumors, mainly carrying deleterious mutations of BRCA1/BRCA2 genes. Only few data are available regarding the cardiac and vascular safety profile of this drug class. We carried out a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palazzo, A., Ciccarese, C., Iacovelli, R., Cannizzaro, M.C., Stefani, A., Salvatore, L., Bria, E., Tortora, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163166/ https://www.ncbi.nlm.nih.gov/pubmed/36893518 http://dx.doi.org/10.1016/j.esmoop.2023.101154

Ejemplares similares

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
por: Imperiali, Claudia E., et al.
Publicado: (2020)

Cardiac rehabilitation performance predicts 1‐year major adverse cardiovascular events
por: Naami, Robert, et al.
Publicado: (2022)

Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response
por: Pasqualoni, Mariangela, et al.
Publicado: (2023)

Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease
por: Armstrong, Ehrin J., et al.
Publicado: (2014)

Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
por: Mal, Kheraj, et al.
Publicado: (2020)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events
por: Gaist, David, et al.
Publicado: (2022)

Comparison of HEAR and HEART Scores for Major Adverse Cardiovascular Events
por: Uyan, Umut
Publicado: (2023)

Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
por: Peluso, Rosario, et al.
Publicado: (2018)

Association of Major Adverse Cardiovascular Events in Patients With Stroke and Cardiac Wall Motion Abnormalities
por: Kamran, Saadat, et al.
Publicado: (2021)

Major Adverse Cardiovascular Events (MACE) in COVID-19 Infection and the Role of Cardiac Biomarkers: A Systematic Literature Review
por: Mahendran, S., et al.
Publicado: (2021)

Necroptosis Drives Major Adverse Cardiovascular Events During Severe COVID-19
por: Wiscovitch-Russo, Rosana, et al.
Publicado: (2023)

Major adverse cardiovascular events are associated with necroptosis during severe COVID-19
por: Wiscovitch-Russo, Rosana, et al.
Publicado: (2023)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Heterogeneous plaque–lumen geometry is associated with major adverse cardiovascular events
por: Gu, Sophie Z, et al.
Publicado: (2023)

Major adverse cardiovascular events in older emergency department patients presenting with non-cardiac medical complaints
por: Zelis, N., et al.
Publicado: (2022)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
por: Tian, Xiaojiang, et al.
Publicado: (2022)

Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention
por: Cai, Anping, et al.
Publicado: (2019)

Cardiac scoring systems, coronary artery disease and major adverse cardiovascular events: A scoping review
por: Premsagar, Preesha, et al.
Publicado: (2023)

Endothelial Dysfunction Is Associated With Major Adverse Cardiovascular Events in Peritoneal Dialysis Patients
por: Lee, Mi Jung, et al.
Publicado: (2014)

Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction
por: Zheng, Meifan, et al.
Publicado: (2020)

Genetic information improves the prediction of major adverse cardiovascular events in the GENEMACOR population
por: Mendonça, Maria Isabel, et al.
Publicado: (2021)

Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection
por: Jiang, Joy, et al.
Publicado: (2023)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

IMPACT OF VACCINATION ON MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG PATIENTS WITH COVID-19
por: Jiang, Joy, et al.
Publicado: (2023)

Ten-year predictors of major adverse cardiovascular events in patients without angina
por: Premsagar, Preesha, et al.
Publicado: (2023)

Major adverse events and atrial tachycardia in Ebstein’s anomaly predicted by cardiovascular magnetic resonance
por: Rydman, Riikka, et al.
Publicado: (2018)

Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset
por: Yamaoka, Kenta, et al.
Publicado: (2022)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
por: Schilder, Jeanne M., et al.
Publicado: (2023)

Major adverse cardiovascular events following partial nephrectomy: a procedure-specific risk index
por: Nasrallah, Ali A., et al.
Publicado: (2022)

SUN-624 Low Risk of Major Adverse Cardiovascular Events After Pancreas Transplantation Alone
por: Kaur, Ravinder Jeet, et al.
Publicado: (2020)

Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events
por: Mani, Venkatesh, et al.
Publicado: (2009)

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
por: Dougados, Maxime, et al.
Publicado: (2023)

Age-Specific Cardiovascular Risk Factors for Major Adverse Cardiac Events in Patients Undergoing Myocardial Perfusion Imaging
por: Megna, Rosario, et al.
Publicado: (2023)

Characteristics of peripheral blood cells are independently related to major adverse cardiovascular events after carotid endarterectomy
por: Overmars, L. Malin, et al.
Publicado: (2023)

Sarcoidosis: comprehensive CMR evaluation and major adverse cardiac events
por: Higgins, Angela Y, et al.
Publicado: (2016)

Identification of an increased lifetime risk of major adverse cardiovascular events in UK Biobank participants with scoliosis
por: Quintero Santofimio, Valentina, et al.
Publicado: (2023)

Newly Diagnosed Atrial Fibrillation Is an Independent Factor for Future Major Adverse Cardiovascular Events
por: Li, Chen-Yu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rq0u2sonrq5pvp0ms07gfc4rua